RxDoctor Payments Data

Zeming Deng, MD

Family Medicine · Midwest City, OKNPI 1659363463

Payments from drug & device makers

$12,964in general payments, 2019–2025

Across 809 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • plus $4K from 36 others

What the payments were for

  • Travel & lodging$160%
  • Food & beverage$12,916100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,964 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$601,636
Medicare patients
362
Services billed
27,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide51$72,275
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$68,637
OzempicSemaglutide44$61,077
FarxigaDapagliflozin Propanediol59$57,195
JardianceEmpagliflozin47$54,053
MounjaroTirzepatide34$35,774
EliquisApixaban29$34,519
JanuviaSitagliptin Phosphate22$30,365
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$10,422
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,513
TradjentaLinagliptin12$6,134
Testosterone11$5,679
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$5,607
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen316$4,307
Atorvastatin Calcium184$2,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,215$108,04985 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,389$76,15173 claims
Novo NordiskOzempic$1,647$61,07744 claims
Boehringer IngelheimJardiance, Tradjenta$529$60,18759 claims
AstraZenecaFarxiga$1,717$57,19559 claims
PfizerEliquis$1,057$34,51929 claims
MerckJanuvia$355$30,36522 claims
AbbVieSynthroid$1,963$1,14112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Midwest City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →